Literature DB >> 30580446

Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: The S1P pathway.

Aliakbar Yousefi-Ahmadipour1, Amir Rashidian2, Mohammad Reza Mirzaei3, Alireza Farsinejad4, Fatemeh PourMohammadi-Nejad5, Mahmoud Ghazi-Khansari2, Jafar Ai1, Sadegh Shirian6, Amir Allahverdi1, Jamileh Saremi1, Somayeh Ebrahimi-Barough1.   

Abstract

Adipose derived mesenchymal stem cells (ASCs) transplantation is a novel immunomodulatory therapeutic tool to ameliorate the symptom of inflammatory bowel disease (IBD). The objective of this study was to investigate the therapeutic effects of combined sufasalazine and ASCs therapy in a rat model of IBD. After induction of colitis in rats, ASCs were cultured and intraperitoneally injected (3 × 106 cells/kg) into the rats on Days 1 and 5 after inducing colitis, in conjunction with daily oral administration of low dose of sulfasalazine (30 mg/kg). The regenerative effects of combination of ASCs and sulfasalazine on ulcerative colitis were assessed by measuring body weight, colonic weight/length ratio, disease activity index, macroscopic scores, histopathological examinations, cytokine, and inflammation markers profiles. In addition, western blot analysis was used to assess the levels of nuclear factor-kappa B (NF-κB) and apoptosis related proteins in colitis tissues. Simultaneous treatment with ASCs and sulfasalazine was associated with significant amelioration of disease activity index, macroscopic and microscopic colitis scores, as well as inhibition of the proinflammatory cytokines in trinitrobenzene sulfonic acid (TNBS)-induced colitis. Moreover, combined ASCs and sulfasalazine therapy effectively inhibited the NF-κB signaling pathway, reduced the expression of Bax and prevented the loss of Bcl-2 proteins in colon tissue of the rats with TNBS-induced colitis. Furthermore, combined treatment with ASCs and sulfasalazine shifted inflammatory M1 to anti-inflammatory M2 macrophages by decreasing the levels of MCP1, CXCL9 and increasing IL-10, Arg-1 levels. In conclusion, combination of ASCs with conventional IBD therapy is potentially a much more powerful strategy to slow the progression of colitis via reducing inflammatory and apoptotic markers than either therapy alone.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  NF-κB; adipose derived mesenchymal stem cells; inflammation; low-dose sulfasalazine

Mesh:

Substances:

Year:  2018        PMID: 30580446     DOI: 10.1002/jcp.27944

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies.

Authors:  Xiao Shi; Qi Chen; Fen Wang
Journal:  Stem Cell Res Ther       Date:  2019-08-23       Impact factor: 6.832

2.  2,4,6-trinitrobenzenesulfonic acid-induced colitis in Rattus norgevicus: a categorization proposal.

Authors:  Mariana Ferreira-Duarte; Tiago Rodrigues-Pinto; Daniela Menezes-Pinto; Marisa Esteves-Monteiro; Salomé Gonçalves-Monteiro; Sara Capas-Peneda; Fernando Magro; Patrícia Dias-Pereira; Manuela Morato; Margarida Duarte-Araújo
Journal:  Exp Anim       Date:  2021-02-03

Review 3.  Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.

Authors:  Meng-Yue Shi; Lian Liu; Fu-Yuan Yang
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.